Timothy Grube, DO
Obstetrics & Gynecology · Frackville, PANPI 1194720870
Payments from drug & device makers
What this record shows
This record is dominated by education: $192,164 of the $260,375 with a category attached, or 73.8%. Intuitive Surgical accounts for 78.1% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2022 at $62,076 and has fallen 57.9% since, to $26,103 in 2025. Among obstetrics & gynecology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 436 payments — averaging $597.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$203K
- AbbVie$52K
- Medtronic$2K
- Astellas Pharma US Inc$482
- Axonics, Inc.$295
- Sumitomo Pharma America, Inc.$269
- plus $2K from 25 others
Across 7 payments — averaging $4307.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$30K
What the payments were for
- Speaking & faculty fees$47,40018%
- Travel & lodging$5,1662%
- Food & beverage$15,6456%
- Education$192,16474%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 152 | $203,343 |
| AbbVie(2 entities) | 105 | $52,390 |
| Medtronic(2 entities) | 23 | $1,659 |
| Astellas Pharma US Inc | 22 | $482 |
| Axonics, Inc. | 11 | $295 |
| Sumitomo Pharma America, Inc. | 16 | $269 |
| Exeltis, USA Inc. | 14 | $239 |
| Pfizer | 15 | $237 |
| Mayne Pharma Commercial LLC | 10 | $142 |
| Myovant Sciences Inc. | 8 | $121 |
| Hologic Sales And Service, LLC | 5 | $120 |
| Therapeuticsmd, Inc. | 7 | $118 |
| AMAG Pharmaceuticals, Inc. | 6 | $102 |
| Momentis Surgical Inc. | 1 | $101 |
| Merck | 4 | $91 |
| Urovant Sciences Inc | 6 | $89 |
| Boston Scientific | 2 | $89 |
| Organon | 5 | $83 |
| Amgen | 5 | $77 |
| Bluewind Medical | 2 | $55 |
| Millicent US Inc | 3 | $49 |
| Radius Health, Inc. | 3 | $42 |
| Coopersurgical, Inc. | 2 | $32 |
| Novo Nordisk | 2 | $31 |
| Johnson & Johnson | 1 | $23 |
| Scynexis, Inc. | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| Olympus America Inc. | 1 | $16 |
| Lupin Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $11 |
| Minerva Surgical, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$202,310
- Orilissa$38,368
- ORIAHNN$18,275
- INTERSTIM$1,015
- Anovo Surgical System$101
How this compares
$260,375 in reported general payments places this provider in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 40 | $36,309 |
| GemtesaVibegron | 26 | $22,566 |
| ProliaDenosumab | 12 | $21,558 |
| PremarinEstrogens, Conjugated | 21 | $7,450 |
| PremproEstrogen,con/M-Progest Acet | 17 | $6,554 |
| Estradiol | 45 | $5,248 |
| ValacyclovirValacyclovir Hcl | 26 | $1,588 |
| ProgesteroneProgesterone, Micronized | 21 | $1,451 |
| Clobetasol Propionate | 13 | $401 |
| Solifenacin Succinate | 27 | $388 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $205 |
| Ibuprofen | 27 | $181 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $167 |
| Bethanechol Chloride | 18 | $167 |
| Oxybutynin Chloride | 11 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $482 | $36,30940 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $269 | $22,56626 claims |
| AmgenProlia | $77 | $21,55812 claims |
| PfizerPremarin, Prempro | $237 | $14,00538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Other obstetrics & gynecology in Frackville
- Stephen KlaskoPhiladelphia$2.2M
- Stephanie SoberPhiladelphia$1.8M
- Barry JacobsonGlen Mills$302K
- Russell StankiewiczLewisburg$202K
- Jamille Nagtalon-RamosPhiladelphia$183K
- Timothy DeimlingMechanicsburg$182K
- Gerald HarkinsMechanicsburg$140K
- Kirthik ParthasarathyWest Reading$103K
- Catherine ChappellPittsburgh$94K
- Joseph PatrunoAllentown$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.